Fidelity SPDR Advertisement
Home > Boards > US OTC > Medical - Equipment >

Solos Endoscopy, Inc. (SNDY)

Add SNDY Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator Marilynt, Bopper155, slazenger7, Aqua
Search This Board:
Last Post: 11/23/2014 11:55:45 PM - Followers: 605 - Board type: Free - Posts Today: 0

= Share Structure - Updated 10/21/2013=
Market Value $2,813,198 Updated 01/28/2014
Shares Outstanding 1,749,488,055 Updated 9/18/2014
Float 1,734,025,196 Updated 9/18/2014
Authorized Shares 2,900,000,000 Updated 9/18/2014
Restricted Shares 15,462,859 Updated 9/18/2014

= Officers/Directors =

Robert Segersten_CEO_President_Treasurer_Director
Amanda Segersten_Secretary_Vice President
Fred Schiemann_CFO_Director

Nevada SOS

Robert Segersten_President of Solos Endoscopy
Robert Segersten, President Treasurer and Director: Mr. Segersten founded Woodbine Optical Corporation in 1991 in order to produce OEM video cameras for the medical marketplace. The company quickly added light sources, video couplers and relay lens to its product offering. Woodbine procured large OEM contracts from companies like Bircher Medical, Olympus, and ConMed. His relationship with Bircher Medical allowed Woodbine the opportunity to acquire the Solos Endoscopy Video division of Bircher. He successfully merged Solos into Woodbine and renamed the company - Solos Endoscopy capitalizing on the strong brand recognition of Solos. He grew the company to approximately $3 million in sales, at which time he was approached by EndoImage and sold Solos in 1994. He stayed on as President until 1996. He remained an advisor to the company until he reacquired ownership in 2000. He is a graduate of Bates College and received his law degree from Boston University.

Amanda Segersten_Vice President of Solos Endoscopy
Amanda Segersten attended Johnson and Wales University and has been employed by Solos Endoscopy since 2000.

Fred Schiemann_CFO of Solos Endoscopy
Fred Schiemann previously served as the Chief Financial Officer of Xtreme Oil & Gas, Inc. Prior to that, he has held CFO positions in several corporations and currently serves as Treasurer of His educational background includes an undergraduate degree from the University of Illinois, Chicago Circle Campus as well as an MBA in taxation from Golden Gate University, Sacramento campus. During his years of practice, he has been involved with many public registrations and structuring of mergers and acquisitions. His current practice includes an emphasis on administration and consulting to small and micro-cap public companies.

= Business Summary =

Solos Endoscopy, Inc. develops and markets technology, applications, medical devices, and procedural techniques for the screening, diagnosis, treatment, and management of medical conditions. It primarily offers rigid endoscopes, hand held surgical instruments, and video equipment for the minimally invasive surgery market. The company's products include digital imaging systems; three-chip and one-chip camera systems, and three-chip cameras; cameras and accessories; rigid scopes comprising laparoscopes, operative scopes, cystoscopes, and scope trays; and endoscopic instruments, such as dissectors, graspers, scissors, needle holders, fan retractors, cautery instruments, insufflation needles, and clip applying forceps. Its products also comprise laparoscopic instruments, including general surgery, lymphadenectomy, gynecology, and thorascopy instruments; trocar and cannula sets, cannulas, trocars, reducer sleeves, and seals; monitors and video carts; video equipment and accessories; illumination instruments, such as fiber optic cables, light port adapters, light sources, and replacement lamps; and insufflators. In addition, Solos offers ENT products for tymplanoplasty, endoscopic sinus surgery, and septorhinoplasty; bariatric instruments; and insulated and non-insulated handles. It markets its products to hospitals, surgery centers, and physician offices through direct sales and it's Web site. The company was formerly known as ViaDux Health, Inc. and changed its name to Solos Endoscopy, Inc. in March 2006. Solos Endoscopy was founded in 1986 and is based in Boston, Massachusetts.

= Company =

About Solos Endoscopy, Inc.:

Solos Endoscopy, Inc. is a healthcare technology company that develops and markets technology,  applications, medical devices and procedural techniques for the screening, diagnosis, treatment and   management of medical conditions. The Company has several dozen products, mainly rigid endoscopes,  hand held surgical instruments and video equipment for the minimally invasive surgery market, all of  which can be found on its website at: The Company markets its products to  hospitals, surgery centers and physician offices.

Additional information on its  FDA approved products is available on the Company's website at:

65 Sprague Street
West B

Boston, MA 02136

The office is approximately 6,000 square feet.

Phone: 617-360-9700

Investor Relations Phone: 1-617-360-9719
Transfer Agent:
Pacific Stock Transfer
4045 South Spencer Street, Ste. 403
Las Vegas, NV 89119
Registered Under Exchange Act: Yes
Regulatory Authority: Security Exchange Commission (SEC)

= Press Releases = 
Solos Endoscopy Receives ISO 13485:2003 Certification From TUV SUD America

Solos Endoscopy and TUV SUD America Schedule Stage 2 ISO 13485 Audit for August 16, 2013

Solos Endoscopy and TUV SUD America Schedule Stage 1 ISO 13485 Audit for February 26, 2013

Solos Endoscopy, Inc. ISO 13485 Certification & CE Mark Project Schedule - MARCH

= Latest Filings =

Year end is December 31st. Quarterly filings are due 45 days after the end of each quarter:

Q1 Jan-Mar 10-Q due May 15th
Q2 Apr-Jun 10-Q due Aug 15th
Q3 Jul-Sep 10-Q due Nov 15th
Q4 Oct-Dec 10-K due Mar 30th (90 days allowed for Q4 which is included in the Annual Report)

= President's Letter/ Information=

August 13, 2013 

Dear Solos Endoscopy, Inc. Shareholders, 

I am very pleased to be able to communicate with our loyal shareholders directly and to give you an 
update on our impressive progress for the second quarter; the three month period ended June 30, 2013. 
Solos Endoscopy, Inc. has been at the forefront of breakthrough medical devices and technologies for the 
treatment and management of diseases for over 25 years. The Company markets over 200 items to the 
endoscopic market and is continuing the development of products that will enhance the ability of medical 
professionals to perform minimally invasive surgical techniques. 
Solos Endoscopy completed the Stage 1 Audit with TÜV SÜD America on Tuesday, February 26, 2013. Solos 
Endoscopy's Quality Manual and 28 Quality System Procedures were reviewed by TÜV SÜD for compliance 
to the international quality system standard ISO 13485:2003, to the European Union's Medical Device 
Directive (MDD 93/42/EEC) and to the Canadian Medical Device Regulations (SOR/98-282). Since the 
completion of the Stage 1 Audit, the Company has been diligently working, with the support of Expert 
Resources, to continually develop, implement and master the Quality Manual and Quality System 

Solos Endoscopy and TÜV SÜD America has scheduled its Stage 2 ISO 13485 Audit to be completed on 
August 16, 2013. Upon successful completion of the Stage 2 Audit, including a review of the Auditor’s report 
and resolution to any corrective actions, Solos will be certified to ISO 13485:2003, the internationally
recognized standard for quality systems for medical device manufacturers. Certification to ISO 13485:2003 
will in turn facilitate Solos Endoscopy obtaining the CE Mark on its MammoView® devices to sell the 
MammoView® in the European Union. According to a 2009 report published by Frost & Sullivan, the 
European Union represents $94 Billion, or 30%, of the worldwide demand for medical instruments. ISO 
13485:2003 certification is also necessary for the company to sell the MammoView® product line in 
Canada. Recently, as part of the process to obtain the CE Mark, Solos Endoscopy has retained Emergo 
Group to act as the Company's authorized representative in Europe. Emergo Group will provide Solos 
assistance related to communications with authorities and importation of Solos instruments into Europe. 
The company previously was successful in completing the Food and Drug Administration (FDA) Level II 
Baseline Inspection in which it received a NAI (No Action Indicated) for the inspection. It is standard for the 
FDA to perform unannounced inspections periodically for medical device manufacturers, and the 
successful inspection by the FDA validates the Company's quality system and its strict adherence to that 
Solos has several exciting new advances in product development that will change the way minimally 
invasive procedures are utilized in the medical field in order to treat and prevent disease. These products 
will allow the physician to examine organs and tissues within the body without the need for intrusive surgery. 
The Company is currently marketing its next generation breast endoscopy system, the MammoView® 
system, for early breast cancer detection. 
Solos Endoscopy’s core business is the development and marketing of medical technology, applications, 
medical devices and procedural techniques for the screening, diagnosis, treatment and management of 
disease and medical conditions. 

Solos Endoscopy 2nd Quarter 2013 Analysis 

Balance Sheet

Solos Endoscopy’s Total Assets decreased to $2,262,785 for the period ended June 30, 2013 from $2,426,883 
for same period in 2012. This represents a decrease of ($164,098), which is mainly attributable to a cash 
and inventory decrease of more than $167,000 for the period ended June 30, 2013 as compared to the 
same period in 2012. 
Solos Endoscopy reduced its Total Liabilities from $214,827 for the period ended June 30, 2012 to just 
$148,000 for period ended June 30, 2013. As a result, the Company has a Positive Net Book Value when it 
posted its financials for the period ended June 30, 2013. 

Income Statement 

Solos Endoscopy showed an increase in sales from $81,752 for period ended June 30, 2012 to $107,955 for 
period ended June 30, 2013. This represents an increase in revenues of $26,203. The Company’s Gross Profit 
increased from $53,214 for period ended June 30, 2012 to $59,520 for the period ended June 30, 2013. The 
Company’s Cost of Goods increased by more than $18,000 as a result of the Company writing off obsolete 
inventory in the 2nd Quarter. 
Solos Endoscopy’s Total Expenses decreased from $642,963 for period ended June 30, 2012 to $177,978 for 
period ended June 30, 2013. The significant decrease in Total Expenses is due to the $450,000 expense the 
Company incurred for stock issued to the CEO in 2012 to guarantee his contract. Otherwise, the Company 
actually reduced its General and Administrative Expense from $192,963 for period ended June 30, 2012 to 
just $177,978 for period ended June 30, 2013. 


The Company decreased its Net Loss for period ended June 30, 2013 by $471,290. The significant financial 
improvement from the same period in 2012 is due to the fact that the Company will not be charged again 
for the issuance of stock to its CEO to guarantee his contract. This improvement of $450,000, combined with 
an increase in sales of $26,203, resulted in a significant turnaround for the Company. According to 
Management, total salaries are only $45,404 or approximately 40% of sales. The Company has spent 
additional monies on professional fees to complete the TUV Audit which is scheduled to take place on 
August 16, 2013. Therefore, Operating Expenses going forward should remain constant. The reduction of 
these onetime expenses, coupled with an expected increase in sales the 3rd and 4th quarters in 2013, should 
result in a very positive end of the year for Solos Endoscopy.
In closing, I want to thank our shareholders for your patience and continued support of Solos Endoscopy. 
We will continue to keep our shareholders updated through regular posting on and 
Company press releases. To learn more information about the Company and its products visit 

Robert Segersten 
President and CEO 
Solos Endoscopy, Inc 
 Solos Endoscopy, Inc.

= TUV SUD America:  CE Mark Certification=

= Charts =

One Year Daily:


  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
#72716  Sticky Note Solos Endoscopy’s MamoView(R) Demonstrates Strong Growth Potential slazenger7 11/12/14 12:10:07 PM
#71767  Sticky Note Letter to shareholders: Warhead 07/18/14 07:52:24 PM
#67301  Sticky Note HERE ARE THE FACTS WHAT WE CAN EXPECT Pennylanepam 01/25/14 06:40:18 PM
#67002  Sticky Note European Union CE Mark Approval Aqua 01/24/14 12:20:35 PM
#62030  Sticky Note Folks, IH Admin [Linda] 08/22/13 03:42:17 PM
#72826   Copying and pasting my old posts doesn't impress slazenger7 11/23/14 11:55:45 PM
#72825   Yeah they would, they could fill in the Warhead 11/23/14 09:58:10 PM
#72824   "No legitimate company would even consider acquiring a Hulk Hogan is God 11/23/14 08:47:32 PM
#72823   Major News coming SOON! Canada/Europe/Strategic Partnership - Watch slazenger7 11/23/14 08:27:01 PM
#72822   They definitely need a partner but doesn't look ravmn 11/23/14 04:33:36 PM
#72821   At least you were right then! lowandaway 11/23/14 03:25:49 PM
#72819   Brother they pulled the SAME "purchase order" carrot Hulk Hogan is God 11/22/14 06:51:22 AM
#72818   Sharing DD: "***SNDY's Constant Massive Dilution/Reverse Split Machine*** Hulk Hogan is God 11/22/14 06:50:35 AM
#72817   Thanks for taking up the good fight slaz, sharkey1 11/22/14 04:21:48 AM
#72816   I find it much more gratifying to have slazenger7 11/22/14 12:13:19 AM
#72815   They are selling them now. Check it out - slazenger7 11/22/14 12:05:53 AM
#72814   None of those. It will happen SOON. slazenger7 11/21/14 11:56:57 PM
#72813   1. They don't even have the Canadian Hulk Hogan is God 11/21/14 11:11:09 PM
#72812   Could happen any day now, I mean any lowandaway 11/21/14 10:23:33 PM
#72810   Good for you! Just remember, that no matter slazenger7 11/21/14 07:05:42 PM
#72809   Try looking at your actual calendar. That report slazenger7 11/21/14 07:00:13 PM
#72808   Where is the Canadian license which was applied ravmn 11/21/14 05:40:08 PM
#72807   That's how I read it, too. 8hobbes9 11/21/14 05:24:57 PM
#72806   Still waiting for positive news!! lowandaway 11/21/14 05:22:53 PM
#72805   Here, "purchase orders" from 2009: Hulk Hogan is God 11/21/14 04:50:22 PM
#72804   Try looking at the actual report: Hulk Hogan is God 11/21/14 04:44:00 PM
#72803   Dude, I'm looking at this, among other things - slazenger7 11/21/14 04:38:32 PM
#72800   Dude, sales DIDN'T increase, what are you looking at? Hulk Hogan is God 11/21/14 03:47:34 PM
#72799   Revenue down for this quarter as well as Hulk Hogan is God 11/21/14 03:29:17 PM
#72798   We do have sales, we just need more. Warhead 11/21/14 03:21:04 PM
#72797   The recent sales increases that are positively impacting slazenger7 11/21/14 01:30:07 PM
#72796   Yes Sir That's why your still holding Right? Blaze2 11/21/14 01:21:32 PM
#72795   Still heading towards .015? lowandaway 11/21/14 12:31:06 PM
#72794   and ? bad like the others rk091161 11/21/14 11:25:06 AM
#72793   Quarterly report posted Philter1972 11/21/14 11:15:30 AM
#72792 slazenger7 11/21/14 09:25:59 AM
#72791   Wouldn't they have to actually sell something first? Hulk Hogan is God 11/20/14 11:09:29 PM
#72790   BINGO! Once again, I think Steritap will deliver the Warhead 11/20/14 05:26:21 PM
#72789   I'm excited myself, I think that people are Aguren 11/20/14 05:22:47 PM
#72788   Sales have DECREASED since that 2009 PR, $395,000 Hulk Hogan is God 11/20/14 04:29:18 PM
#72787   Thanks for that observation. Yes, SNDY's sales are slazenger7 11/20/14 04:25:38 PM
#72786   Looking forward to upcoming news. Warhead 11/20/14 04:07:31 PM
#72785   It proves nothing of the sort. It Hulk Hogan is God 11/20/14 03:53:24 PM
#72784   Thanks! Yes, it proves sales are continuing now, slazenger7 11/20/14 03:37:13 PM
#72783   It proves that "purchase orders" don't mean sales Hulk Hogan is God 11/20/14 02:37:00 PM
#72782   Thanks for posting that! That is a fantastic slazenger7 11/20/14 02:26:15 PM
#72781   Things have "changed"? Um, look at this Hulk Hogan is God 11/20/14 12:32:45 PM
#72780   Things have finally changed for the positive -Sales slazenger7 11/20/14 11:04:59 AM
#72779   "Any clear thinking investor has to ask themselves Hulk Hogan is God 11/20/14 08:17:28 AM
#72778   SNDY - Negotiating sales contracts in Canada. Europe slazenger7 11/20/14 07:43:28 AM
#72777   "SNDY has been bragging about % sales growth Hulk Hogan is God 11/20/14 06:20:00 AM
#72776   "How are they going to generate "a steady Hulk Hogan is God 11/20/14 06:15:12 AM
#72775   You're right, I see the date now in slazenger7 11/19/14 11:37:14 PM
#72774   Sorry, but they have until Friday. The Aguren 11/19/14 11:25:39 PM
#72773   Is this the really big news that we lowandaway 11/19/14 11:19:17 PM